The Montreal Children's Hospital
Montreal, Quebec, H4A 3J1, Canada
NCT Number: NCT03378830
The study type is a prospective observational cohort study of children undergoing adenotonsillectomy (T&A). The study will recruit the annual caseload of children undergoing T&A at the Montreal Children's Hospital, QC, Canada; aiming for 200 children. There are no interventions.
The purpose of this study is to determine the severity and duration of postoperative pain after T&A and to link the severity of this pain with the severity of sleep disordered breathing.
Looking for future studies?
Notify Me2 year–12 year
All sexes
Observational
Montreal, Quebec, H4A 3J1, Canada
Adenotonsillectomy (T&A) is one or the most common surgeries performed in children. Even though T&A is considered a painful surgery, it is often scheduled as a day surgery and parents manage the postoperative pain at home. Historically, the home analgesic following adenotonsillectomy consisted of a combination of acetaminophen and codeine. In June 2013, Health Canada no longer recommended the use of codeine in children less than 12 years of age. Thus in current practice the discharge analgesic is a combination of ibuprofen, acetaminophen and oral rescue morphine. This shift in practice has occurred globally as well as in our institution without evaluating the impact on analgesia at home following T&A.
The published literature reports that as many as 50% of children managed with the acetaminophen/codeine regimen visit a primary care physician for the management of pain/infection following T&A and a high proportion of these children are prescribed an opioid. This practice is of concern for the following reasons. Sleep disordered breathing (SDB) is the most common indication for T&A in children. In some children the sleep disturbance meets the diagnostic criteria for obstructive sleep apnea (OSA). A subset of children, with severe OSA are more sensitive to both the analgesic and respiratory effects of opioids. In these children, an age-appropriate dose of opioids may result in an overdose.
Study Design:
Pain will be measured in hospital and at home with validated pain scores. The primary outcome measure is the Parents' Postoperative Pain Measure (PPPM), a valildated, established metric, with good construct and content validity, for the repeated evaluation of pain following surgery in the home environment. Parents will be asked to record the both the pain scores, twice daily for 14 days.
A secondary outcome measure will be the self report of pain from the children. Two validated pain scales will be used. For pre-verbal children, the Face, Legs, Activity, Cry and Consolability (FLACC) pain scale will be used. This 0-10 scale has shown good reliability, validity and relevance in clinical practice for children's less than 4 years of age for post-operative pain. For older children the modified modified Faces Pain Scale (FPS-R) will be used. The 0-10 metric score is validated and reliable for children aged 4 - 16 years.
Outcome measure Time Frame Parents will be asked to record the PPPM and either the FLACC or the FPS-R, twice daily for 14 days in a pain diary. The change in pain scores over 14 days will be evaluated.
Preoperatively the severity of the SDB will be assessed, with the Snoring, Trouble Breathing, UnRefreshed (STBUR) questionnaire; a 5-item questionnaire.
Primary Aim:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: We are asking the parents to record the PPPM twice daily for 14 days.
The PPPM is a validated 15 item questionnaire that requires a Yes or No response. The maximum total score is 15. A total score above 6 indicates clinically relevant pain.
Time frame: The STBUR will be administered once during the preoperative evaluation of the child.
The STBUR is a 5 item questionnaire that requires a yes or no response. The STBUR has been validated to predict 1) perioperative respiratory adverse events and 2) opioid related respiratory adverse event. The maximum score is 5. A total score of 3 or more is associated with in increased risk of respiratory adverse events.
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04948541
Apnea, Craniomandibular Disorders
Roma, RM, Italy
View Trial DetailsNCT04928157
Apnea, Chronic Pain
San Diego, California, United States
View Trial DetailsNCT03919955
Apnea, Dyssomnias
Boston, Massachusetts, United States
View Trial DetailsNCT06050720
Apnea, Dyssomnias
Stoke-on-Trent, United Kingdom
View Trial Details